Incidence of Idiopathic Intracranial Hypertension in Individuals With Gonadotropin-Releasing Hormone Analogue Treatment for Gender Dysphoria in Sweden-Reference-Cited by-同舟云学术

Incidence of Idiopathic Intracranial Hypertension in Individuals With Gonadotropin-Releasing Hormone Analogue Treatment for Gender Dysphoria in Sweden

Published:2023-07-01 Issue:7 Volume:177 Page:726
ISSN:2168-6203
Container-title:JAMA Pediatrics
language:en
Short-container-title:JAMA Pediatr

Author:

Karamanis Georgios¹,Frisell Thomas²,Holmberg Mats³,Halldin Maria⁴,Sylvén Sara¹,Skalkidou Alkistis⁵,Papadopoulos Fotios C.¹

Affiliation:

1. Department of Medical Sciences, Psychiatry, Uppsala University Hospital, Uppsala, Sweden

2. Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

3. ANOVA, Karolinska University Hospital, Stockholm, Sweden

4. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

5. Department of Women's and Children's Health, Obstetrics and Gynecology, Uppsala University, Uppsala, Sweden

Abstract

This cohort study examines the incidence of idiopathic intracranial hypertension (IHH) among individuals in Sweden undergoing gonadotropin-releasing hormone analogue (GnRHa) treatment for gender dysphoria.

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology and Child Health

Link

https://jamanetwork.com/journals/jamapediatrics/articlepdf/2804410/jamapediatrics_karamanis_2023_ld_230013_1688135487.43906.pdf

Reference4 articles.

1. Idiopathic intracranial hypertension.;Wall;Neurol Clin,2010

2. Population-based incidence and clinical characteristics of idiopathic intracranial hypertension.;Sundholm;Acta Neurol Scand,2017

3. A national Swedish case-control study investigating incidence and factors associated with idiopathic intracranial hypertension.;Sundholm;Cephalalgia,2021

4. Food and Drug Administration. Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists. July 1, 2022. Accessed February 17, 2023. https://www.fda.gov/media/159663/download